Excelsior Biopharma Inc. (TPEX:6496)
Taiwan
· Delayed Price · Currency is TWD 26.20
-0.85 (-3.14%)
At close: Mar 9, 2026
Excelsior Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 898.26 | 861.91 | 771.56 | 671.76 | 1,338 | Upgrade
|
| Revenue Growth (YoY) | 4.22% | 11.71% | 14.86% | -49.81% | -7.29% | Upgrade
|
| Cost of Revenue | 538.1 | 479.82 | 464.63 | 384.59 | 1,045 | Upgrade
|
| Gross Profit | 360.17 | 382.1 | 306.93 | 287.17 | 293.35 | Upgrade
|
| Selling, General & Admin | 438.24 | 377.21 | 324.57 | 277.82 | 241.65 | Upgrade
|
| Research & Development | 96.09 | 83.62 | 62.51 | 42.32 | 56 | Upgrade
|
| Operating Expenses | 531.77 | 463.07 | 388.06 | 316.47 | 302.12 | Upgrade
|
| Operating Income | -171.6 | -80.97 | -81.13 | -29.29 | -8.77 | Upgrade
|
| Interest Expense | -7.77 | -8.02 | -6.37 | -4.35 | -4.54 | Upgrade
|
| Interest & Investment Income | 1.26 | 3.42 | 5.24 | 4.17 | 0.41 | Upgrade
|
| Earnings From Equity Investments | 2.18 | 0.25 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | -4.94 | -1.55 | -1.28 | 1.81 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.58 | 2.87 | 1.86 | 3.68 | 0.9 | Upgrade
|
| EBT Excluding Unusual Items | -172.34 | -87.39 | -81.95 | -27.06 | -10.19 | Upgrade
|
| Other Unusual Items | - | 0 | - | 1.07 | 0.16 | Upgrade
|
| Pretax Income | -172.34 | -87.39 | -81.95 | -25.99 | -10.03 | Upgrade
|
| Income Tax Expense | 10.83 | 11.32 | 9.06 | 7.76 | 5.62 | Upgrade
|
| Net Income | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 | Upgrade
|
| Net Income to Common | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 | Upgrade
|
| Shares Outstanding (Basic) | 46 | 46 | 46 | 46 | 47 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 46 | 46 | 46 | 47 | Upgrade
|
| Shares Change (YoY) | 0.07% | 0.42% | 0.15% | -1.42% | -5.56% | Upgrade
|
| EPS (Basic) | -3.97 | -2.14 | -1.98 | -0.74 | -0.34 | Upgrade
|
| EPS (Diluted) | -3.97 | -2.14 | -1.98 | -0.74 | -0.34 | Upgrade
|
| Free Cash Flow | -175.67 | -356.95 | -170.41 | -2.3 | 52.95 | Upgrade
|
| Free Cash Flow Per Share | -3.81 | -7.74 | -3.71 | -0.05 | 1.14 | Upgrade
|
| Gross Margin | 40.10% | 44.33% | 39.78% | 42.75% | 21.92% | Upgrade
|
| Operating Margin | -19.10% | -9.40% | -10.51% | -4.36% | -0.66% | Upgrade
|
| Profit Margin | -20.39% | -11.45% | -11.80% | -5.03% | -1.17% | Upgrade
|
| Free Cash Flow Margin | -19.56% | -41.41% | -22.09% | -0.34% | 3.96% | Upgrade
|
| EBITDA | -99.92 | -65.64 | -69.31 | -16.41 | 6.39 | Upgrade
|
| EBITDA Margin | -11.12% | -7.62% | -8.98% | -2.44% | 0.48% | Upgrade
|
| D&A For EBITDA | 71.68 | 15.33 | 11.82 | 12.88 | 15.15 | Upgrade
|
| EBIT | -171.6 | -80.97 | -81.13 | -29.29 | -8.77 | Upgrade
|
| EBIT Margin | -19.10% | -9.40% | -10.51% | -4.36% | -0.66% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.